Answers are grounded in this paper and cite their sources.
Objectives Conventional glucocorticoid (GC) treatment poses significant risks for opportunistic infections due to its suppressive impact on CD4 + T cells. This study aimed to explore the mechanisms by which GCs modulate the functionality of CD4 + T cells during infection. Methods We consistently measured FOXP3, inflammatory cytokines and phospho‐S6 ribosomal protein levels in CD4 + T cells from patients undergoing conventional GC treatment. Using Foxp3 EGFP animals, we investigated the dynamic activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway and its correlation with the immunoregulatory function of CD4 + T cells under the influence of GCs. Results GCs dynamically altered the expression pattern of FOXP3 in CD4 + T cells, promoting their acquisition of an active T regulatory (Treg) cell phenotype upon stimulation. Mechanistically, GCs undermined the kinetics of the mTORC1 pathway, which was closely correlated with phenotype conversion and functional properties of CD4 + T cells. Dynamic activation of the mTORC1 signaling modified the GC‐dampened immunoregulatory capacity of CD4 + T cells by phenotypically and functionally bolstering the FOXP3 + Treg cells. Interventions targeting the mTORC1 pathway effectively modulated the GC‐dampened immunoregulatory capacity of CD4 + T cells. Conclusion These findings highlight a novel mTORC1‐mediated mechanism underlying CD4 + T cell immunity in the context of conventional GC treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: